ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered...

Presentation to highlight advancements in Hoth's clinical pipeline, including HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program targeting KIT-driven tumors NEW YORK, Oct....

Tsingke proudly concluded its participation in BIO-Europe 2024, held from November 4 to 6 in Stockholm, Sweden. As one of the premier global events for the biotechnology, pharmaceutical, and...

Turacoz Group, a leading medical communication company, recently participated in BioEurope's 18th edition held in Barcelona from March 18th to 20th, 2024. The event, known for connecting the...

Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, is announcing its selection by Life Sciences British Columbia (LSBC) for the 2023 'Company to Watch'